Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 54, Issue 1, 2010, Pages 92-99

  Gabriel, M ^a   Andergassen, U ^a   Putzer, D ^a   Kroiss, A ^a   Waitz, D ^a   Von Guggenberg, E ^a   Kendler, D ^a   Virgolini, I J ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Individualized medicine; Neuroendocrine tumors; Radiopharmaceuticals

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LAN GA 68; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LAN LU 177; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LAN Y 90; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID PHENYLALANINE TYROSINE OCTREOTIDE GA 68; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID PHENYLALANINE TYROSINE OCTREOTIDE Y 90; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE OCTREOTATE LU 177; ANTINEOPLASTIC AGENT; ARGININE; INDIUM 111; LUTETIUM 177; LYSINE; PEPTIDE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; YTTRIUM 90;

ABDOMINAL DISCOMFORT; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BRONCHUS CARCINOID; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CREATININE BLOOD LEVEL; DENDRITIC RETICULUMSARCOMA; DOSIMETRY; FEMALE; HAIR LOSS; HEMATOLOGIC DISEASE; HEMOGLOBINEMIA; HUMAN; KIDNEY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; PALLIATIVE THERAPY; PANCREATIC NEUROENDOCRINE TUMOR; PERFORMANCE; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; QUALITY OF LIFE; REMISSION; SIDE EFFECT; SMALL BOWEL NEUROENDOCRINE TUMOR; THROMBOCYTOPENIA; THYROID CARCINOMA; TUMOR VOLUME; VOMITING; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; ISOTOPE LABELING; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952487451     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Kwekkeboom DJ, Krenning EP, Bakker WH, Oei HY, Kooij PP, Lamberts SW. Somatostatin analogue scintigraphy in carcinoid tumours. EurJ Nucl Med 1993;20:283-292 (Pubitemid 23233998)
2. Dejong M, Breeman WA, Kwekkeboom DJ, Valkema R, Krenning EP. Tumor imaging and therapy using radiolabeled somatostatin analogues. Ace Chem Res 2009;42:873-880
3. Jamar F, Fiasse R, Leners N, Pauwels S. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safty, efficacy and impact on patient management. J Nucl Med 1995;36:542-549
4. Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y etal. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997;38:853-858
5. Kisker O, Bartsch D, Weinel RJ, Joseph K, Welcke UH, Zaraca F et al. The value of somatostatin-receptor scintigraphy in newly diagnosed endocrine gastroenteropancreatic tumors. J Am Coll Surg 1997;184:487-492
6. Seregni E, Chiti A, Bombardieri E. Radionuclide imaging of neuroendocrine tumours: biological basis and diagnostic results. Eur J Nucl Med 1998;25:639-658 (Pubitemid 28297840)
7. 111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1998;20: 716-731
8. Frilling A, Malago M, Martin H, Broelsch CE. Use of somatostatin receptor scintigraphy to image extrahepatic metastases of neuroendocrine tumors. Surgery 1998;124:1000-1004
9. Krausz Y, Bar-Ziv J, De Jong R, Ish-Shalom S, Chisin R, Shibley N et al. Somatostatin receptor scintigraphy in the management of gastroenteropancreatic tumors. Am J Gastroenterol 1998;93: 66-70. (Pubitemid 29065516)
10. Chiti A, Briganti V, Fanti S, Monetti N, Masi R, Bombardieri E. Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours. QJ Nucl Med 2000;44:42-49 (Pubitemid 30325952)
11. Gotthardt M, Dirkmorfeld LM, Wied MU, Rinke A, Behe MP, Schlieck A etal. Influence of somatostatin receptor scintigraphy and CT/MRI on die clinical management of patients with gastrointestinal neuroendocrine tumors: an analysis in 188 patients. Digestion 2003;68:80-85
12. Reubi J-C, Häcki WH, Lamberts SWJ. Hormones producing gastroin-testinal tumors contain a high density of somatostatin receptors. J Clin Endocrinol Metab 1987;65:1127-1134
13. 111In-DTPA-octreotide for diagnosis of somatostatin receptor expressing tumors. J Nucl Med 2003;44: 708-716
14. 99mTc-EDDA/ HYNIC-TyK3)-octreotide for staging and follow-up of patients with neuroendocrine gastro-entero-pancreatic tumors. QJ Nucl Med Mol Imaging 2005;49:237-244
15. 177Lu-DOTAO,Tyr3] octreotate in patients with endocrine gastropancreatic tumors. J Cin Oncol 2005;23:2754-2762
16. 177Lu- DOTA O,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124-2130
17. 177Lu-DOTAO,Tyr3] octreotate. J Clin Oncol 2004;22:2724-2729 (Pubitemid 41103761)
18. 111In-DOTA- lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2006;33:532-540
19. Traub-Weidinger T, von Guggenberg E, Dobrozemsky G, Kendler D, Eisterer W, Bale R etal. First experiences with ga-68-dota-lanreotide pet in tumor patients. Eur J Nucl Med Mol Imaging 2006;33 (Supplement 2): S123.
20. Gabriel M, Andergassen U, Putzer D, Decristoforo C, von Guggenberg E, Heute D etal. Innsbruck experience with targeted radionuclide therapy using different radiolabeled somatostatin analogs. Eur J Nucl Med Mol Imaging 2007;34 (Supplement 2):S220.
21. Rolleman EJ, Melis M, Valkema R, Boerman OC, Krenning EP, de Jong M. Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging 2009 (In press).
22. 68Gallium-DOTA-TyrO-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and Computed Tomography. J Nucl Med 2007;48: 508-518.
23. 90Y-DOTA-TOC. J Nucl Med 2005;46:1310-1316.
24. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L etal. New guidlines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, national cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-216
25. Oberg K, Jelic S; ESMO Guidelines Working Group. Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommondations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19: Suppl.2; ii104-105.
26. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med 2009;50:1427-1434
27. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992;10:239-253 (Pubitemid 23008970)
28. De Jong M, Bernard B, De Bruin E, Van Gameren A, Bakker WH, Visser TJ et al. Internalization of radiolabelled [DTPAO]octreotide and [DOTAO,Tyr3] octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Comm 1998;19:283-288
29. 90Y-labeled somatostatin analogs. J Nucl Med 2005;46 Suppl 1:13S-17S.
30. Forrer F, Valkema R, Kwekkeboom DJ, de Jong M, Krenning EP. Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metabol 2007;21:111-129
31. Van Essen M, Krenning EP, Kam BL, de Jong M, Valkema R, Kwekkeboom DJ. Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol 2009;5:382-392